Morphic Holding, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | |
|---|---|---|---|---|---|---|
| Revenue | $521,000 | $70.8M | $19.8M | $44.9M | $17.0M | $3.4M |
| Operating income | −$178.7M | −$63.4M | −$95.8M | −$47.2M | −$47.0M | −$5.2M |
| Net income | −$152.1M | −$59.0M | −$95.5M | −$45.0M | −$43.3M | −$5.2M |
| Total assets | $722.5M | $368.6M | $426.3M | $242.4M | $247.4M | $189.3M |
| Total liabilities | $25.5M | $19.5M | $89.6M | $97.2M | $106.5M | $102.0M |
| Equity | $697.0M | $349.1M | $336.7M | $145.2M | $140.9M | −$52.6M |
| EPS (diluted) | $-3.59 | $-1.55 | $-2.67 | $-1.47 | $-2.69 | — |
| Shares out. | 39.5M | 37.1M | 32.4M | 30.5M | 16.1M | — |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- −34296.7%
- Net margin
- −29192.9%
- Return on equity
- −21.8%
- Return on assets
- −21.1%
- Return on capital (ROCE)
- −25.6%
- Liabilities / assets
- 3.5%
- Debt / equity
- 0.04×
- Book value / share
- $17.63
- Revenue growth (YoY)
- −99.3%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Altman Z″ (distress)
- 31.31safe
- Accruals / assets
- −5.5%clean
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 4 warning● 3 good- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsAug 16, 2024
- Entered a material agreement · Other material eventJul 8, 2024
- Shareholder voteJun 5, 2024
- Entered a material agreement · Terminated a material agreementApr 26, 2024
- Results of operationsApr 25, 2024
- Regulation FD disclosureMar 12, 2024
- Results of operationsFeb 22, 2024
- Results of operations · Regulation FD disclosureJan 12, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.